86 related articles for article (PubMed ID: 26883286)
21. CA125 decline in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy.
Richardson DL; Seamon LG; Carlson MJ; O'Malley DM; Fowler JM; Copeland LJ; Cohn DE
Gynecol Oncol; 2008 Nov; 111(2):233-6. PubMed ID: 18768214
[TBL] [Abstract][Full Text] [Related]
22. ACOG Committee Opinion No. 396. Intraperitoneal chemotherapy for ovarian cancer.
American College of Obstetricians and Gynecologists
Obstet Gynecol; 2008 Jan; 111(1):249. PubMed ID: 18165421
[TBL] [Abstract][Full Text] [Related]
23. Phase II trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancer.
Husain A; Sabbatini P; Spriggs D; Fennelly D; Aghajanian C; Barakat R; Curtin J; Venkatraman E; Hoskins W; Markman M
Gynecol Oncol; 1999 Apr; 73(1):96-101. PubMed ID: 10094887
[TBL] [Abstract][Full Text] [Related]
24. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
Landrum LM; Moore KN; Myers TK; Lanneau GS; McMeekin DS; Walker JL; Gold MA
Gynecol Oncol; 2009 Feb; 112(2):337-41. PubMed ID: 19041126
[TBL] [Abstract][Full Text] [Related]
25. Volasertib Versus Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: A Randomized Phase II Groupe des Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire Study.
Pujade-Lauraine E; Selle F; Weber B; Ray-Coquard IL; Vergote I; Sufliarsky J; Del Campo JM; Lortholary A; Lesoin A; Follana P; Freyer G; Pardo B; Vidal L; Tholander B; Gladieff L; Sassi M; Garin-Chesa P; Nazabadioko S; Marzin K; Pilz K; Joly F
J Clin Oncol; 2016 Mar; 34(7):706-13. PubMed ID: 26755507
[TBL] [Abstract][Full Text] [Related]
26. Wilms tumor protein 1 (WT1)-- not only a diagnostic but also a prognostic marker in high-grade serous ovarian carcinoma.
Taube ET; Denkert C; Sehouli J; Kunze CA; Dietel M; Braicu I; Letsch A; Darb-Esfahani S
Gynecol Oncol; 2016 Mar; 140(3):494-502. PubMed ID: 26721227
[TBL] [Abstract][Full Text] [Related]
27. An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer.
Berry E; Matthews KS; Singh DK; Buttin BM; Lurain JR; Alvarez RD; Schink J
Gynecol Oncol; 2009 Apr; 113(1):63-7. PubMed ID: 19201457
[TBL] [Abstract][Full Text] [Related]
28. Annexin A2 and S100A10 are independent predictors of serous ovarian cancer outcome.
Lokman NA; Pyragius CE; Ruszkiewicz A; Oehler MK; Ricciardelli C
Transl Res; 2016 May; 171():83-95.e1-2. PubMed ID: 26925708
[TBL] [Abstract][Full Text] [Related]
29. Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer.
Milczek T; Klasa-Mazurkiewicz D; Emerich J; Kobierski J
Acta Obstet Gynecol Scand; 2009; 88(4):463-7. PubMed ID: 19235559
[TBL] [Abstract][Full Text] [Related]
30. MiR-378 as a biomarker for response to anti-angiogenic treatment in ovarian cancer.
Chan JK; Kiet TK; Blansit K; Ramasubbaiah R; Hilton JF; Kapp DS; Matei D
Gynecol Oncol; 2014 Jun; 133(3):568-74. PubMed ID: 24680769
[TBL] [Abstract][Full Text] [Related]
31. Who really benefits from intraperitoneal chemotherapy for advanced ovarian cancer? A treatment-free survival analysis of the AICE trial.
Xiang L; Shen L; Chen Y; Guo Y; Jiang R; Zhang W; Jia H; Wu Z; Zang R
BJOG; 2022 Nov; 129 Suppl 2():32-39. PubMed ID: 36485070
[TBL] [Abstract][Full Text] [Related]
32. Intraperitoneal chemotherapy for advanced epithelial ovarian malignancy: lessons learned.
Bunting M; Chan W; Brand A; Blomfield P
Aust N Z J Obstet Gynaecol; 2009 Dec; 49(6):667-71. PubMed ID: 20070720
[TBL] [Abstract][Full Text] [Related]
33. Correlation of extreme drug resistant assay results and progression-free survival following intraperitoneal chemotherapy for advanced ovarian cancer.
Pant AC; Diaz-Montes T; Tanner E; Ahmad S; Giuntoli RL; Holloway RW; Bristow RE
J Chemother; 2010 Aug; 22(4):270-4. PubMed ID: 20685633
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of survivin, X-linked inhibitor of apoptosis protein and second mitochondria-derived activator of caspases expression in advanced non-small-cell lung cancer patients.
Chen P; Li J; Ge LP; Dai CH; Li XQ
Respirology; 2010 Apr; 15(3):501-9. PubMed ID: 20210890
[TBL] [Abstract][Full Text] [Related]
35. Longitudinal Modulation of Loco-Regional Immunity in Ovarian Cancer Patients Receiving Intraperitoneal Chemotherapy.
Suarez Mora A; Strange M; Fang Y; Uygun I; Zhang L; Tseng GC; Kalinski P; Edwards RP; Vlad AM
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428740
[TBL] [Abstract][Full Text] [Related]
36. "From chemo to chemo"-the temporal paradox of chemotherapy.
Moskalewicz M; Popova Y; Wiertlewska-Bielarz J
Support Care Cancer; 2021 Jul; 29(7):3429-3431. PubMed ID: 33619675
[TBL] [Abstract][Full Text] [Related]
37. Does ezrin play a predictive role in cancer patients undergoing radiotherapy and/or chemotherapy?
Cihan YB
Hum Pathol; 2018 Oct; 80():247-248. PubMed ID: 29940285
[No Abstract] [Full Text] [Related]
38. Single Gene Prognostic Biomarkers in Ovarian Cancer: A Meta-Analysis.
Willis S; Villalobos VM; Gevaert O; Abramovitz M; Williams C; Sikic BI; Leyland-Jones B
PLoS One; 2016; 11(2):e0149183. PubMed ID: 26886260
[TBL] [Abstract][Full Text] [Related]
39. Characteristics of 10-year survivors of high-grade serous ovarian carcinoma.
Dao F; Schlappe BA; Tseng J; Lester J; Nick AM; Lutgendorf SK; McMeekin S; Coleman RL; Moore KN; Karlan BY; Sood AK; Levine DA
Gynecol Oncol; 2016 May; 141(2):260-263. PubMed ID: 26968641
[TBL] [Abstract][Full Text] [Related]
40. Impact of molecular profiling on overall survival of patients with advanced ovarian cancer.
Herzog TJ; Spetzler D; Xiao N; Burnett K; Maney T; Voss A; Reddy S; Burger R; Krivak T; Powell M; Friedlander M; McGuire W
Oncotarget; 2016 Apr; 7(15):19840-9. PubMed ID: 26942886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
